About Us

Overview

Interaction between proteins and chemical compounds is an inherently complex problem which is of significant importance to research and development processes across a broad range of sectors. Moleculomics have developed powerful structural modelling and virtual screening platforms capable of simulating real life conditions by virtue of increased understanding of molecular interaction at the whole system level.

The Moleculomics technologies utilize the latest High Performance Computing approaches and are applied extensively to wild type, mutations and polymorphic variation within organisms. They are used to identify interactions, not only at the targets of interest, but also elsewhere across the entire proteome or across several proteomes.

Increased scale of understanding of molecular interaction enables research and development times to be reduced by more rapid and wider identification of target hits while simultaneously reducing the risk of adverse or off-target interactions.

Moleculomics is the only company offering open-ended lead discovery, toxicity screening and protein network identification, that is completely unlimited in reach, and that is applied across multiple genomes.

More information about the Moleculomics team can be found here.

Moleculomics technologies have been extensively validated through cutting edge contract research as identified below;

. . .

2012

Incorporation of Moleculomics Ltd

2013

Awarded first contract –
Contractor for TSB funded “Design of zinc peptidases with enhanced thermostability or thermolability”

2013

Awarded first Centre for Defence Enterprise (CDE) contract
“A multi-genome in silico platform for identification and screening of antimicrobial targets” 

Read More

2014

High Performance Computing Wales Research and Innovation Award for 2 PhD Students

Read More

2014

Access to Masters placements for 2 students leading to permanent placements

Read More

2014

Gained CompTIA Trustmark Accreditation

Read More

2015

Awarded NC3R’s CRACK-IT Challenge
“Linking off-target MIEs and AOPs by in silico benchmarking of the ToxCast database” collaborating with Unilever and Dow Agrosciences

Read More

2015

Incorporation of Moleculomics In Silico Discovery Inc.
A wholly owned Canadian subsidiary

Read More

2016

Completion of TargetPath
The main IT platform in use in the British defence industry for identifying new anti-bacterial compounds

2017

Launch of Human3DProteome (Read more)

Our approach to consultancy and outsourced work is flexible and collaborative.  Our company values recognise the importance of confidentiality – our services are hosted by proprietary software and project-dedicated hardware. It is our strategy to help develop and enhance intellectual property through trusted partnership.

Company Team
Find out more about the international team behind Moleculomics
Read more
Our Services
An overview of the current range of services which we have to offer
Read more
News
Latest company and industry news from the biosimulation sector
Read more
Contact Us
Contact a company representative to discuss your next project
Read more

START TYPING AND PRESS ENTER TO SEARCH